Cellectis to Report Third Quarter Financial Results on November 7, 2025
Cellectis (NASDAQ: CLLS) announced it will report its third quarter 2025 financial results for the period ended September 30, 2025 on Friday, November 7, 2025 after the U.S. market close.
The company said the press release will be posted in the Investors section of its website and that no conference call will be held to discuss results; investor inquiries may be directed to investors@cellectis.com.
Cellectis (NASDAQ: CLLS) ha annunciato che pubblicherà i risultati finanziari del terzo trimestre 2025 per il periodo terminato il 30 settembre 2025 venerdì 7 novembre 2025 dopo la chiusura del mercato statunitense.
L'azienda ha detto che il comunicato stampa sarà pubblicato nella sezione Investitori del proprio sito web e che non verrà organizzata alcuna conferenza telefonica per discutere i risultati; le richieste degli investitori possono essere inviate a investors@cellectis.com.
Cellectis (NASDAQ: CLLS) anunció que reportará sus resultados financieros del tercer trimestre de 2025 para el periodo terminado el 30 de septiembre de 2025 el viernes 7 de noviembre de 2025 después del cierre del mercado de Estados Unidos.
La compañía indicó que el comunicado de prensa se publicará en la sección de Inversores de su sitio web y que no se realizará ninguna llamada de conferencia para discutir los resultados; las consultas de los inversores pueden dirigirse a investors@cellectis.com.
Cellectis (NASDAQ: CLLS)는 2025년 9월 30일 종료된 기간에 대한 2025년 3분기 재무실적을 2025년 11월 7일 금요일 미국 증시 마감 후에 발표할 것이라고 발표했습니다.
회사는 보도자료가 자사 웹사이트의 투자자 섹션에 게시되며 결과를 논의하기 위한 컨퍼런스 콜은 개최되지 않는다고 밝혔으며; 투자자 문의는 investors@cellectis.com로 보내면 됩니다.
Cellectis (NASDAQ: CLLS) a annoncé qu'elle publiera ses résultats financiers du troisième trimestre 2025 pour la période se terminant le 30 septembre 2025 le vendredi 7 novembre 2025 après la clôture du marché américain.
La société a indiqué que le communiqué de presse sera publié dans la section Investisseurs de son site Web et qu'aucune conférence téléphonique ne sera organisée pour discuter des résultats ; les demandes des investisseurs peuvent être adressées à investors@cellectis.com.
Cellectis (NASDAQ: CLLS) gab bekannt, dass sie ihre Finanzergebnisse des dritten Quartals 2025 für den Zeitraum bis zum 30. September 2025 am Freitag, dem 7. November 2025 nach Börsenschluss in den USA bekannt geben wird.
Das Unternehmen erklärte, dass die Pressemitteilung im Bereich Investoren auf seiner Website veröffentlicht wird und dass kein Conference Call zur Besprechung der Ergebnisse abgehalten wird; Anfragen von Investoren können an investors@cellectis.com gerichtet werden.
Cellectis (NASDAQ: CLLS) أعلنت أنها ستعلن عن نتائجها المالية للربع الثالث من عام 2025 للمدة المنتهية في 30 سبتمبر 2025 يوم الجمعة 7 نوفمبر 2025 بعد إغلاق السوق الأميركي.
قالت الشركة إن البيان الصحفي سيُدرج في قسم المستثمرين على موقعها الإلكتروني وأنه لن تُعقد مكالمة مؤتمرات لمناقشة النتائج؛ يمكن توجيه استفسارات المستثمرين إلى investors@cellectis.com.
- None.
- None.
NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the third quarter 2025 ending September 30, 2025 on Friday, November 7, 2025 after the close of the US market.
The press release will be available in the Investors section of Cellectis’ website: https://www.cellectis.com/en/investors/press-releases/
Cellectis will not host a conference call to discuss these results. Our investors relations team remains available for questions at investors@cellectis.com
About Cellectis
Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic approach for CAR T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to develop gene therapies in other therapeutic indications. With its in-house manufacturing capabilities, Cellectis is one of the few end-to-end gene editing companies that controls the cell and gene therapy value chain from start to finish. Cellectis’ headquarters are in Paris, France, with locations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more, visit www.cellectis.com and follow Cellectis on LinkedIn and X.
For further information on Cellectis, please contact:
Media contacts:
Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93
Investor Relations contact:
Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com
Attachment
FAQ
When will Cellectis (CLLS) release Q3 2025 financial results?
Where can I find the Cellectis (CLLS) Q3 2025 press release?
Will Cellectis (CLLS) host a conference call for the November 7, 2025 results?
How can investors contact Cellectis (CLLS) with questions about Q3 2025 results?
What reporting period does Cellectis' November 7, 2025 release cover?
